Reports Q3 revenue $67.455M, consensus $72.81M. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, “We continued to see revenue growth with significant gross margin improvement in the third quarter of 2025. Amtagvi demand is increasing as we integrate our community treatment centers to drive earlier treatment and better outcomes for patients. We are building a successful commercial business, while advancing our high value development programs to address significant unmet medical needs in patients with solid tumor cancers.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- IOVA Earnings this Week: How Will it Perform?
- Iovance Biotherapeutics’ Lifileucel Therapy: Promising Developments and Market Potential Justify Buy Rating
- Iovance Biotherapeutics reports clinical data from Phase 2 IOV-LUN-202 trial
- Iovance Biotherapeutics price target lowered to $9 from $20 at H.C. Wainwright
- Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study